156 related articles for article (PubMed ID: 16217280)
1. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.
Davies B; Chen J; Modugno F; Weissfeld J; Landsittel D; Dhir R; Nelson J; Getzenberg RH
J Urol; 2005 Nov; 174(5):1767-70. PubMed ID: 16217280
[TBL] [Abstract][Full Text] [Related]
2. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury.
Davies B; Chen JJ; McMurry T; Landsittel D; Lewis N; Brenes G; Getzenberg RH
Urology; 2005 Oct; 66(4):908-11. PubMed ID: 16230180
[TBL] [Abstract][Full Text] [Related]
4. Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy.
Dong ZL; Lu ZP; Wang HZ; Zhang LY; Wang ZP; Zhang YF; Ma BL
Urol Int; 2011; 87(4):445-9. PubMed ID: 22056470
[TBL] [Abstract][Full Text] [Related]
5. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
6. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
[TBL] [Abstract][Full Text] [Related]
7. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
[TBL] [Abstract][Full Text] [Related]
8. Lack of progress in early diagnosis of bladder cancer.
Araki M; Nieder AM; Manoharan M; Yang Y; Soloway MS
Urology; 2007 Feb; 69(2):270-4. PubMed ID: 17320662
[TBL] [Abstract][Full Text] [Related]
9. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
10. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer.
Müller H; Haug U; Rothenbacher D; Stegmaier C; Brenner H
J Urol; 2008 Oct; 180(4):1309-12; discussion 1312-3. PubMed ID: 18707695
[TBL] [Abstract][Full Text] [Related]
12. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.
Eissa S; Shabayek MI; Ismail MF; El-Allawy RM; Hamdy MA
IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180
[TBL] [Abstract][Full Text] [Related]
14. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
15. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
Shariat SF; Ashfaq R; Karakiewicz PI; Saeedi O; Sagalowsky AI; Lotan Y
Cancer; 2007 Mar; 109(6):1106-13. PubMed ID: 17311310
[TBL] [Abstract][Full Text] [Related]
16. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
17. Bladder neck preservation during radical retropubic prostatectomy and postoperative urinary continence.
Razi A; Yahyazadeh SR; Sedighi Gilani MA; Kazemeyni SM
Urol J; 2009; 6(1):23-6; discussion 26. PubMed ID: 19241337
[TBL] [Abstract][Full Text] [Related]
18. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
Moussa O; Abol-Enein H; Bissada NK; Keane T; Ghoneim MA; Watson DK
J Urol; 2006 Jun; 175(6):2312-6. PubMed ID: 16697865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]